Integrated, Quality-Driven DEL for Drug Discovery
DNA-encoded libraries (DELs) represent a powerful approach to hit identification and rapid lead generation. However, for too long, DELs have often been treated primarily as a “number game”. Our DNA-encoded library services deliver a different approach with a fully integrated platform, designed to maximise hit quality and accelerate discovery timelines
By combining screening services, advanced library design, and rigorous quality control, Novalix DNA-encoded libraries collection (NovaDEL) ensures the identification of drug-like confirmed hits and reliable downstream progression for drug discovery programs.
Library Design and Construction
NovaDEL is carefully engineered to possess drug-like properties. As a specialized DNA-encoded library CRO, Novalix designs and synthesizes high-quality libraries tailored for effective DEL screening and hit discovery.
The construction of DELs involves rigorous building block selection, optimized encoding techniques, and thoroughly validated synthetic methodologies. Medicinal chemists play a central role throughout the design process, overseeing the monitoring of physicochemical properties and chemical space.
This approach ensures comprehensive coverage of chemical diversity and reliable generation of drug-like compounds for effective DNA-encoded library screening and downstream hit identification.
Learn more: https://novalix.com/2025/evaluating-the-diversity-and-target-addressability-of-dels-using-scaffold-analysis/
Quality Control & Screening
Quality controls are embedded throughout our entire DEL workflow from automated library synthesis to DEL screening and hit validation stages.
Analysis of screening results with in-house tools ensures data integrity and reproducibility, minimizing artefacts and false positives during the DEL screening workflow.
These robust processes in DEL data analysis ensure high-confidence datasets and reliable data.
Hit Confirmation & Follow-Up
Novalix DEL workflow includes orthogonal DEL hit validation, via off-DNA resynthesis, and biophysical confirmation.
This integrated process reliably distinguishes genuine binders from artefacts and supports DEL hit expansion strategies to develop promising chemical series for lead optimization.
Our expert medicinal chemists analyze structure affinity relationships (SAFIRs) to identify high-value chemical series emerging from DNA-encoded library screening campaigns.
Structured Integration of Cheminformatics & AI
Novalix integrates cheminformatics, together with advanced AI-driven DEL approaches, machine learning DEL models, and generative AI drug discovery technologies to facilitate data-driven decision making and improve hit quality throughout the DEL workflow.
These AI-assisted hit selection strategies support improved DEL data analysis and enable the identification of hits beyond the screened DEL chemical space.
Leveraging both machine learning DEL models and generative AI drug discovery, NovaDEL expands chemical exploration and improves hit prioritization.
This strategy has been validated in internal case studies and international AI/ML competitions.
Learn more: https://novalix.com/2025/combining-del-and-ai-for-hit-findings-hype-or-reality/
Pharma-Proven Results
NovaDEL has delivered drug-like actionable hits for a range of targets, including those considered intractable by conventional methods such as HTS or fragment screening.
Through its integrated DNA-encoded libraries screening, advanced library design and synthetic services, Novalix provides reliable hit discovery and rapid progression toward lead optimisation.
Each project is supported by transparent reporting and collaborative review, ensuring client confidence in outcomes.
Learn more: DEL vs HTS vs Fragment Screening Explainer
Discuss your target with Novalix’s DEL experts — contact us.